Table 1. Evaluation of prognostic role of endothelial CD105 on OS and DFS in univariate and multivariate analyses.
| |
Crude estimates |
Adjusted estimates |
||||
|---|---|---|---|---|---|---|
| HR | (95% CI) | P-value | HR | (95% CI) | P-value | |
|
OS in all cohort (Patients
n=102) | ||||||
| Age | 1.01 | 0.98–1.04 | 0.71 | |||
| Sex (M/F) | 1.72 | 0.70–4.24 | 0.24 | |||
| Stage (M1/M0) | 3.81 | 1.71–8.45 | 0.001 | 2.19 | 0.92–5.20 | 0.075 |
| CD105 tertiles (3rd/2nd/1st) |
0.41 |
0.25–0.69 |
<0.001 |
0.48 |
0.28–0.85 |
0.011* |
|
DFS (Patients
n=87) | ||||||
| Age | 1.02 | 0.98–1.05 | 0.44 | |||
| Sex (M/F) | 2.73 | 0.79–9.46 | 0.11 | |||
| Leibovich risk groups (Low/intermediate/high) | 4.23 | 2.19–8.17 | <0.001 | 3.84 | 1.93–7.62 | <0.001* |
| CD105 Tertiles (3rd/2nd/1st) | 0.46 | 0.25–0.83 | 0.010 | 0.65 | 0.33–1.30 | 0.224 |
Abbreviations: CD105=cluster of differentiation molecule 105; CI=confidence interval; DFS=disease-free survival; F=female; HR=hazard ratio; M=male; M0=non-metastatic group; M1=metastatic group; OS=overall survival
*P<0.05 (statistically significant difference).